DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Asoprisnil
Asoprisnil
Abnormal Uterine Bleeding: Strategies for Management”
Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
Stems for Nonproprietary Drug Names
Asoprisnil: a Selective Progesterone Receptor Modulator
EC313-A Tissue Selective SPRM Reduces the Growth and Proliferation of Uterine Fbroids in a Human Uterine Fbroid Tissue Xenograft Model Hareesh B
Selective Progesterone Receptor Modulators in Gynaecological Therapies
(12) United States Patent (10) Patent No.: US 8,173,626 B2 Hausknecht (45) Date of Patent: May 8, 2012
Asoprisnil the Progesterone Receptor Modulator Bleeding in Women And
Stembook 2018.Pdf
The Spectrum of Endometrial Pathology Induced by Progesterone Receptor Modulators
Tepzz 85476¥B T
Selective Progesterone Receptor Modulators (Sprms): Progesterone Receptor Action, Mode of Action on the Endometrium and Treatment Options in Gynaecological Therapies
(12) United States Patent (10) Patent No.: US 9,156,877 B2 Klar Et Al
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Expulsion of a Uterine Myoma in a Patient Treated with Ulipristal Acetate Frederic Chantraine1, Gaelle Poismans1, Julia Nwachuku2, Elke Bestel2 & Michelle Nisolle1
Transdermal Delivery System for Hormones and Steroids
Abnormal Uterine Bleeding1,2,3
Progesterone Receptor Ligands for the Treatment of Endometriosis: the Mechanisms Behind Therapeutic Success and Failure
Top View
Oral Contraceptive Pills
(12) United States Patent (10) Patent No.: US 9,096,639 B2 Klar Et Al
Customs Tariff - Schedule Xxi - 1
Downloaded from Future Drug Design
Ulipristal Acetate) Under Section 36 of the Medicines Act 1981 CONFIDENTIAL
Hormonal Therapy for Endometriosis: from Molecular Research to Bedside
Progesterone Receptor NR3C3
Prodrugs of the Selective Progesterone Receptor
WO 2012/121767 Al 13 September 2012 (13.09.2012)
An Update on Developments in Female Hormonal Contraception
Drug Monographs
Gold Standard Drug Monographs
Endometriosis: the Role of Pharmacotherapy
Safety and Efficacy of the Selective
A 12-Month Extension Study to Evaluate the Safety and Efficacy Of
New Selective Progesterone Receptor Modulators and Their Impact on the RANK/RANKL Complex Activity
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Bioinformatics Analysis of Essential Genes in NF1 and CDKN2A Null Cancer Cell Lines
Oup Humupd Dmy020 577..598 ++
Pharmacological Treatment of Uterine Fibroids
Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/PSM/QSM/2006.3